Skip to main content

and
  1. No Access

    Article

    Further explanations about the role of thyroid scintigraphy in the era of TIRADS

    Pierpaolo Trimboli, Joerg Bojunga, Maurilio Deandrea, Francesco Frasca in Endocrine (2024)

  2. Article

    Open Access

    Papillary thyroid carcinoma: ≤ 10 mm does not always mean pN0. A multicentric real-world study

    The incidence of papillary thyroid carcinoma (PTC) is increasing and PTC ≤ 10 mm (PTMC) accounts for most new diagnoses. PTMCs are not always low risk, as detection of lymph nodes metastasis (LNM) may occur. T...

    Stefano Amendola, Tommaso Piticchio, Lorenzo Scappaticcio in Updates in Surgery (2024)

  3. Article

    Open Access

    Reappraising the role of thyroid scintigraphy in the era of TIRADS: A clinically-oriented viewpoint

    Thyroid nodules (TNs) are a common entity, with the majority being benign. Therefore, employing an accurate rule-out strategy in clinical practice is essential. In the thyroid field, the current era is signifi...

    Pierpaolo Trimboli, Joerg Bojunga, Maurilio Deandrea, Francesco Frasca in Endocrine (2024)

  4. No Access

    Article

    Cinque anni di trattamento con GH ricombinante a somministrazione settimanale \(\mathit{vs}\) quotidiana. Estensione di uno studio di fase 2

    Salvatore Volpe, Francesco Frasca in L'Endocrinologo (2023)

  5. Article

    Open Access

    Prevalence and significance of indeterminate calcitonin values in patients with thyroid nodules: A systematic review and meta-analysis

    Although calcitonin (Ctn) measurement is recognized as the most accurate diagnostic test for medullary thyroid carcinoma (MTC), its routine execution is not universally accepted for several reasons, including ...

    Tommaso Piticchio, Francesco Frasca in Reviews in Endocrine and Metabolic Disorde… (2023)

  6. Article

    Open Access

    Nuove strategie di indagine delle linfoadenopatie nel carcinoma tiroideo

    L’identificazione delle metastasi linfonodali è fondamentale nella gestione iniziale dei pazienti con noduli tiroidei sospetti, in quanto può modificare la tipologia dell’intervento chirurgico, e nella gestion...

    Dario Tumino, Tommaso Piticchio, Francesco Frasca in L'Endocrinologo (2023)

  7. Article

    Open Access

    Associazione tra la sindrome metabolica e le caratteristiche clinico-patologiche del carcinoma papillifero tiroideo

    Il progressivo incremento dell’incidenza di carcinoma papillifero tiroideo nella popolazione mondiale può essere solo in parte attribuito alla maggiore diffusione nella pratica clinica della diagnostica ecogra...

    Tommaso Piticchio, Francesco Frasca in L'Endocrinologo (2022)

  8. Article

    Open Access

    Agonisti del recettore del GLP1 e infiammazione: non solo compenso glicemico

    I farmaci agonisti del recettore del Glucagon-like peptide 1 (GLP1) sono ormai da diversi anni protagonisti nella gestione terapeutica del paziente affetto da diabete mellito tipo 2. Oltre alla significativa effi...

    Gabriele Costanzo, Francesco Frasca in L'Endocrinologo (2022)

  9. No Access

    Article

    Onset of Marine-Lenhart syndrome and Graves’ ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis

    Immune checkpoint blockade therapy may lead to thyroid dysfunction in 3–7% of treated patients. Alemtuzumab is a CD52 inhibitor leading to thyroid dysfunction in approximately 40% of patients. A female patient...

    Rosario Le Moli, Marco Russo, Pasqualino Malandrino, Veronica Vella in Hormones (2021)

  10. Article

    Open Access

    Endocrinopatie e anemie / anemie ed endocrinopatie: una si(pali)ndrome spesso misconosciuta

    È comune osservazione nella pratica clinica che, spesso, i deficit endocrini si accompagnano ad anemie di vario grado. È anche noto che alcune specifiche anemie quali la talassemia possono essere associate a d...

    Tommaso Piticchio, Francesco Frasca in L'Endocrinologo (2020)

  11. No Access

    Article

    Il ruolo della tireoglobulina ultrasensibile nel follow-up del carcinoma differenziato tiroideo

    Dario Tumino, Francesco Frasca in L'Endocrinologo (2020)

  12. No Access

    Article

    Validità dei sistemi di classificazione ecografica nell’identificare i noduli tiroidei da non sottoporre all’agoaspirato

    La prevalenza dei noduli tiroidei nella popolazione generale è in continuo incremento, e per almeno la metà dei noduli sottoposti a FNA il risultato della citologia è benigno. I sistemi di classificazione ecog...

    Adriano Naselli, Dario Tumino, Francesco Frasca in L'Endocrinologo (2020)

  13. No Access

    Article

    Selenium exerts protective effects against oxidative stress and cell damage in human thyrocytes and fibroblasts

    Selenium, incorporated into specific seleno-enzymes, is essential to proper thyroid function and protect cells from oxidative damage induced by H2O2 during thyroid hormone synthesis. Several studies indicated tha...

    Rosaria M. Ruggeri, Angela D’Ascola, Teresa M. Vicchio, Salvatore Campo in Endocrine (2020)

  14. No Access

    Article

    Challenges in the treatment of parathyroid carcinoma: a case report

    Parathyroid carcinoma (PC) is a rare neoplasm with a high rate of recurrence and an indolent course. It is frequently functional, causing nearly 1% of the cases of primary hyperparathyroidism (HPT), and in som...

    Marco Russo, Graziella Borzì, Marturano Ilenia, Francesco Frasca in Hormones (2019)

  15. Article

    Open Access

    IRF5 promotes the proliferation of human thyroid cancer cells

    Interferon Regulatory Factor 5 is a transcription factor that regulates the expression of genes involved in the response to viral infection and in the stimulation of the immune system. Moreover, multiple studi...

    Michele Massimino, Paolo Vigneri, Manuela Fallica, Annamaria Fidilio in Molecular Cancer (2012)

  16. No Access

    Article

    In thyroid cancer cell lines expression of periostin gene is controlled by p73 and is not related to epigenetic marks of active transcription

    Periostin expression is a feature of the epithelial-mesenchymal transition, which occurs during cancer progression. Previous reports indicate that periostin expression is related to tumour aggressiveness.

    Cinzia Puppin, Nadia Passon, Francesco Frasca, Riccardo Vigneri in Cellular Oncology (2011)

  17. No Access

    Article

    IGF and Insulin Receptor Signaling in Breast Cancer

    Major molecular abnormalities in breast cancer include the deregulation of several components of the IGF system. It is well recognized that the epithelial breast cancer cells commonly overexpress the IGF-I rec...

    Antonino Belfiore, Francesco Frasca in Journal of Mammary Gland Biology and Neoplasia (2008)

  18. No Access

    Article

    Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor

    The Hepatocyte Growth Factor (HGF) and its receptor Met are physiological regulators of cell migration. HGF and Met have also been implicated in tumor progression and metastasis. We show here that the tyrosine...

    Francesco Frasca, Paolo Vigneri, Veronica Vella, Riccardo Vigneri in Oncogene (2001)

  19. No Access

    Article

    Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism

    IGF-II, produced by breast cancer epithelial and stromal cells, enhances tumor growth by activating the IGF-I receptor (IGF-I-R) via autocrine and paracrine mechanisms. Previously we found that the insulin rec...

    Laura Sciacca, Angela Costantino, Giuseppe Pandini, Rossana Mineo in Oncogene (1999)